TMS Co., Ltd Logo

TMS Co., Ltd

Develops small molecule drugs from natural compounds for the global pharmaceutical market.

4891 | T

Overview

Corporate Details

ISIN(s):
JP3544960002
LEI:
Country:
Japan
Address:
府中市府中町一丁目9番地京王府中1丁目ビル11階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TMS Co., Ltd. is a biotechnology company engaged in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, and medical devices. The company focuses on developing small molecule drug candidates derived from natural compound libraries, collaborating with academic institutions to bridge scientific discoveries with the global pharmaceutical market. Its research includes the development of SMTPs (Small Molecule Therapeutic Products), which have shown potential in promoting thrombolysis, suppressing inflammation, and providing antioxidation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:41
Report Publication Announcement
確認書
Japanese 7.9 KB
2025-10-15 08:40
Interim Report
半期報告書-第22期(2025/03/01-2025/12/31)
Japanese 212.5 KB
2025-05-30 03:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.5 KB
2025-05-30 03:18
Registration Form
確認書
Japanese 7.9 KB
2025-05-30 03:17
Governance Information
内部統制報告書-第21期(2024/03/01-2025/02/28)
Japanese 21.1 KB
2025-05-30 03:15
Annual Report
有価証券報告書-第21期(2024/03/01-2025/02/28)
Japanese 2.9 MB
2025-04-09 09:05
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-03-14 07:58
Registration Form
有価証券届出書(組込方式)
Japanese 407.4 KB
2025-02-28 07:37
Legal Proceedings Report
臨時報告書
Japanese 18.5 KB
2025-02-06 09:01
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2024-10-15 08:18
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-10-15 08:15
Interim Report
半期報告書-第21期(2024/03/01-2025/02/28)
Japanese 176.1 KB
2024-07-12 08:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-07-12 08:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/03/01-2024/05/31)
Japanese 125.8 KB
2024-05-29 03:27
Registration Form
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all TMS Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TMS Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TMS Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PureTech Health plc Logo
A clinical-stage biotherapeutics firm developing new medicines for devastating diseases.
United States of America
PRTC
PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America
PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America
PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland
CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America
QNTM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France
ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America
QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America
QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America
QNRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.